Cargando…
Case report: Idiopathic pulmonary fibrosis induced by nab-paclitaxel: A rare complication
Background: Ovarian cancer is one of the deadliest gynecological cancers, with the most advanced disease and poor survival. Although BRCA genes play a key role in maintaining genomic stability and providing the possibility of clinically individualized treatments, with the emergence of new and more a...
Autores principales: | Shen, Jiahui, Wen, Zhongyong, Lin, Jingxia, Su, Huiwen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9995582/ https://www.ncbi.nlm.nih.gov/pubmed/36909189 http://dx.doi.org/10.3389/fphar.2023.1094844 |
Ejemplares similares
-
Durable response to the combination of pembrolizumab and nab-paclitaxel in a metastatic extrahepatic cholangiocarcinoma: A case report and literature review
por: Tan, Sirui, et al.
Publicado: (2022) -
Case report: Remarkable response to sintilimab, lenvatinib, and nab-paclitaxel in postoperative metastatic chemotherapy-resistant combined hepatocellular-cholangiocarcinoma
por: Zhou, Nan, et al.
Publicado: (2023) -
Laryngopharyngeal pH Monitoring in Patients With Idiopathic Pulmonary Fibrosis
por: Su, Yiliang, et al.
Publicado: (2021) -
Perspectives of PDE inhibitor on treating idiopathic pulmonary fibrosis
por: Yang, Xudan, et al.
Publicado: (2023) -
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
por: Mei, Qianru, et al.
Publicado: (2022)